The clinical activity of the DNA methyltransferase inhibitors 5-azacitidine and 2Ј-deoxy-5-azacytidine in myelodysplastic syndromes (MDS) suggests that epigenetic modulation of gene transcription may play an important pathogenetic role in the development and expression of these diseases. Approximately 50% of patients treated with these compounds experience hematologic improvement, making these the most active single agents for unselected patients with MDS. Responses include complete and partial hematologic responses. Two randomized trials have shown that the use of these drugs significantly alters the natural history of MDS compared with supportive care. Histone deacetylase inhibitors, which may also impact the expression of genes through epigenetic mechanisms, seem to have measurable activity in MDS in preliminary studies. Histone deacetylase inhibitors are most likely used in combination with other agents, including DNA methyltransferase inhibitors. Despite the clinical activity of these classes of drugs, there is no conclusive evidence that their clinical activity is attributable to their impact on the epigenome. Such information will be critical in the development of more effective congeners and drug combinations in ongoing attempts to improve the outcome of patients with MDS. (JNCCN 2006;4:83-90) 
The notion of targeted therapies in cancer implies the rational design or identification of drugs that positively or negatively impact on a particular cellular pathway or regulatory mechanism critical for the survival, proliferation, or metastatic potential of the neoplasm. To date, targeted therapies include drugs that appear truly target-specific but were developed empirically (e.g., all-trans retinoic acid [ATRA] in acute promyelocytic leukemia); antibody-based approaches that target specific cancer cells and normal counterparts (e.g., rituximab, denileukin); active drugs designed to target a particular pathway but whose clinical activity may not derive from the original target (e.g., farnesyl transferase inhibitors in acute myeloid leukemia without ras mutations); and active drugs designed to target a pathway whose activity does derive from the original target (e.g., imatinib mesylate).
The explosive growth of knowledge concerning epigenetic regulation of gene transcription has led to considerable interest in the development of therapies that modulate gene transcription in cancer cells pharmacologically. Epigenetic changes refer to heritable but potentially reversible modifications of DNA and chromatin that regulate gene transcription but that are not caused by irreversible changes such as mutations or deletions. The best-studied epigenetic changes are cytosine methylation, particularly in CpG dinucleotides in gene promoter regions, associated with transcriptional silencing, 1 and a complex variety of posttranslational modifications to lysine-rich tails of histones, associated with specific transcriptional output. These changes are collectively referred to as the histone code. 2 Transcriptional silencing associated with methylation of CpG islands in gene promoters is widespread in cancer. 1 Although these and other epigenetic changes seem to be attractive targets for cancer therapeutics, such approaches are currently limited by the complexity of epigenetic transcriptional control and the lack of specificity of available pharmacologic agents. Nonetheless, reversal of aberrant promoter methylation can be effected through inhibition of the enzymes responsible for maintaining the methylation pattern, DNA methyltransferases (DNMT). In addition, various compounds that lead to histone lysine acetylation through inhibition of histone deacetylases (HDAC) are under clinical investigation.
The historical development of DNMT inhibitors for the treatment of myelodysplastic syndromes (MDS) most resembles the development of ATRA for acute promyelocytic leukemia. Development of these drugs was based on empiric in vitro observations unrelated to the knowledge of specific methylated genes involved with the pathogenesis or expression of these disorders. The identification of the DNMT inhibitors 5-azacitidine (5AC) and 2Ј-deoxy-5-azacitidine (decitabine [DAC] ) as the two most active single agents for the treatment of MDS (with the probable exception of lenalidomide in patients with abnormalities of chromosome 5q3) demonstrates the clinical feasibility and activity of drugs that target epigenetic changes. However, the mechanism underlying the clinical activity of these drugs remains uncertain. This review details the development of DNMT and HDAC inhibitors in MDS and the current understanding of the relationship between these drugs' putative molecular targets and their clinical activity.
Clinical Activity of DNA Methyltransferase Inhibitors in MDS
Both 5AC and DAC were initially studied as classic cytotoxic agents for the treatment of acute myeloid leukemia (AML). 4, 5 Jones and Taylor 6 noted that treatment of mouse embryo cells with 5AC inhibited the methylation of newly synthesized DNA in a dose-dependent fashion. This treatment was associated with induction of cell differentiation to form muscle cells. Both drugs can reverse the methylation of a wide variety of gene promoters, often associated with re-expression of the transcriptionally silenced gene products. 1 Exposure to azacytosine analogues is associated with induction of p21 WAF1/CIP1 (an unmethylated gene) and concomitant cell cycle arrest and can induce apoptosis. 7, 8 In addition to p21, 5AC and DAC induce expression of p53 and GADD45. 9, 10 The mechanisms underlying these events are not well understood.
Researchers investigated 5AC for treating MDS after results showed it could be effective for treating hemoglobinopathies through induction of hemoglobin F. [11] [12] [13] The investigation was based on the concept of effecting more normal differentiation in hematopoietic cells. In the initial trial of 5AC in MDS, it was administered as a continuous intravenous infusion 14 In a successor phase II study, the drug was administered subcutaneously at the same dose schedule. This study treated 67 patients with high-risk MDS; comparable results were presented in abstract form. 15 In Cancer and Leukemia Group B (CALGB), Silverman et al. 16 conducted a confirmatory phase III trial in which patients with all FAB subtypes of MDS and chronic myelomonocytic leukemia (CMML) were randomly assigned to the subcutaneous administration of 5AC or supportive care. Patients with low-risk MDS were required to have significant hematopoietic failure. After 4 months of supportive care, patients in the control arm who met specific exit criteria could cross over to receive 5AC. Patients in the supportive care arm who developed AML as defined by more than 30% blasts could receive 5AC if blast percentage did not exceed 40%. Patients in the 5AC arm had dosage increased by 33% if no response was noted after 57 days (2 cycles of treatment). Patients experiencing complete response (CR) received 3 additional cycles of drug; patients with less than CR continued to receive drug until CR or relapse.
This phase III trial of 191 patients established this regimen as the most active single-agent therapy for MDS and led to the approval of 5AC by the Food and Drug Administration for the treatment of all subsets of MDS patients. The hematologic response rate in the 5AC arm was 60%, including CR (7%), PR (16%), and hematologic improvement (37%), compared with 5% hematologic improvement in the observation arm (in each case, improved neutrophils or platelet counts in the context of progression to AML).
In patients initially assigned to supportive care who crossed over, the response to 5AC was 49% (10% CR, 4% PR, 33% hematologic improvement). Median time to initial response was 64 days; median time to best response was 93 days. Median duration of response was 15 months. Toxicities included mild nausea and vomiting and worsening cytopenias before development of hematologic responses. Patients assigned to the 5AC arm had a median time to AML progression or death of 21 months, compared with 12 months among patients in the supportive care arm (including those who crossed over to receive 5AC). For 15% of the patients, MDS transformed to AML as a first event, compared with 38% in the supportive care arm. A companion quality-of-life study showed improvement in physical functioning, dyspnea, psychosocial distress, and positive affect in patients on 5AC. Patients in the supportive care arm had stable or worsening quality-of-life parameters. The researchers noted improvements in fatigue, physical functioning, dyspnea, and well-being after crossover. 17 DAC underwent parallel development for the treatment of MDS. As with 5AC, formal dose finding was not performed. DAC was initially administered as a 3-day continuous infusion to 29 elderly patients with high-risk MDS either at 40 or 50 mg/m 2 /d. Of these patients, 15 showed a response, including 8 CRs. 18 In subsequent studies, DAC was administered as a 4-hour intravenous infusion, 3 times daily, for 3 days (total daily dose, 45 mg/m 2 ). Subjects included patients with high-risk MDS or CMML and transfusion-dependent patients with refractory anemia and refractory anemia with ringed sideroblasts. Courses were repeated every 6 weeks for 6 cycles. 19 In these studies, 66 patients were treated and 32 patients showed response, including 9 21 Patients were to receive 2 cycles after CR occurred; patients with less than CR were to continue treatment until disease progression. In the treatment arm, 9% of patients developed CR, 8% developed PR, and 13% experienced hematologic improvement. In contrast, only 7% of patients experienced hematologic improvement in the supportive care arm. Median time to response was 3.2 months, with median duration of response 9.5 months. Median time to AML or death was 12.1 months in the DAC arm compared with 7.8 months in the supportive care arm.This difference was not statistically significant. 22 A randomized phase II study in which patients received doses according to 1 of 3 schedules, each delivering 100 mg/m 2 of DAC per course, attempted to establish optimum dose scheduling of DAC. These schedules consisted of 10 mg/m 2 intravenously over 1 hour daily for 10 doses, 20 mg/m 2 intravenously over 1 hour daily for 5 doses, or 20 mg/m 2 subcutaneously daily for 5 doses. All dose schedules resulted in CRs. 23 The parallel experience with 5AC and DAC in MDS provides compelling evidence that DNMT inhibitors as a class have important clinical activity for the treatment of MDS. Both drugs induce hematologic responses in approximately 50% to 60% of patients, including complete clinical and cytogenetic responses. Although pharmacodynamic differences may exist between the drugs because 5AC is incorporated into RNA and DNA 24 whereas DAC is incorporated into DNA alone, current differences in efficacy and toxicity probably relate to differences in relative dose schedules and routes of administration.
A critical difference in study design is in duration of therapy. The CALGB phase III trial of 5AC specified ongoing treatment of patients who experienced less than CR; patients who experienced CR received 3 additional cycles after remission. In contrast, the European studies of DAC administered only 6 cycles of treatment. The greater remission duration in the 5AC study may be because of the prolonged administration of drug to most patients with response, suggesting a potential role for maintenance therapy. Although the North American phase III trial called for ongoing treatment of patients with less than PR, the median number of cycles delivered was only 2.
The current empiric dosing schedules are probably not optimal for either drug for the treatment of MDS.
Practice patterns in the community have not yet been studied. Anecdotally, practitioners have been challenged with the administration of the drug in office settings for 7 sequential days. The expected hematologic toxicity of 5AC during the first cycles of administration and the requirement of 4 cycles to assess response have not been appreciated by all practitioners and may have led to some patients receiving inadequate trials of this drug. Similar problems may apply to DAC if it becomes commercially available.
Relationship Between Clinical Activity and Epigenetic Changes
The marked activity of DNMT inhibitors for the treatment of MDS affords the opportunity to establish whether the clinical application of these drugs can be attributed to re-expression of cell regulatory genes through reversal of promoter methylation and presumed downstream changes in chromatin conformation and gene expression. These remain important unresolved questions.
Analytic techniques for measuring plasma concentrations of 5AC have only recently been developed. Administration of 5AC subcutaneously at doses from 25 to 75 mg/m 2 in patients with hematologic malignancies and solid tumors led to dose-dependent increases in maximal plasma concentration (C max ), with a half-life of 0.75 to 1.5 hours. At 50 mg/m 2 , the mean C max was 706 ng/mL, or 2.9 mcmol/L. This concentration should be adequate for DNMT inhibition. 25 In a separate study, mean peak plasma concentration after subcutaneous administration of 75 mg/m 2 was 687 ng/mL, and mean half-life was 0.69 hours. 26 Pharmacokinetics of DAC have not been determined using current analytic techniques, nor have they been performed for doses currently under investigation.
Momparler et al. 5 initially addressed the issue of whether clinical administration of azacytosine nucleosides is associated with changes in DNA methylation. The investigators isolated leukemic cells from 2 patients (acute lymphoblastic leukemia and chronic myelogenous leukemia in blast phase) receiving decitabine as a continuous infusion (1 mg/kg/h). The cells were incubated with radiolabeled deoxycytidine before isolation and hydrolysis of the DNA. Highpressure liquid chromatography was then used to determine incorporation of the labeled cytosine into DNA-associated cytosine and 5-methylcytosine. Although total incorporation of the labeled cytosine significantly decreased, the ratio of 5-methylcytosine to total cytosine also decreased by 70% to 80%, suggesting that methylation was specifically diminished. The dose of DAC administered was high by current standards; in addition, the impact of in vivo administration of other antimetabolites on the relative 5-methylcytosine:total cytosine ratio was not studied.
Recent studies directly investigating reversal of promoter methylation in cells from patients treated with DNMT inhibitors have been inconclusive. Lübbert et al. 27 used a polymerase chain reaction (PCR)-based technique (Ms-SNuPE) to detect changes in methylation of the p15 INK4B promoter in bone marrow mononuclear cells of MDS patients treated with DAC. p15 is currently the gene known to be most frequently methylated in primary samples of MDS bone marrow cells [28] [29] [30] ; methylation of p15 is correlated with bone marrow blast percentage in these patients. 31 p15 methylation was quantitatively decreased in 9 of 12 evaluable DAC-treated patients. 27 Three evaluable patients who experienced CR all showed decreased p15 methylation; however, methylation reversal was not required for response in other patients with lesser responses. Bisulfite sequencing of the p15 promoter in 4 patients suggested that decitabine treatment induced gradual changes in promoter methylation, rather than elimination of clones containing methylated p15 promoters through cytotoxicity.
Issa et al. 32 examined p15 methylation in patients treated in a dose-finding study of DAC administered at significantly lower doses than in the European studies and U.S. phase III study. The investigators studied methylation in peripheral blood mononuclear cells using a PCR-based technique known as COBRA (combined bisulphite restriction analysis). No significant differences were found in the mean percentage of p15 promoter methylation before treatment between patients who experienced response and those who did not nor in the change in mean or median p15 methylation. However, by the investigators' admission, the cells studied (peripheral blood mononuclear cells) may not have been optimally informative and the assay used may not have been sufficiently robust to detect biologically important changes. Additionally, focusing on mean percentage of methylation may have obscured important changes in individual patients.
This group is now focusing on the methylation of noncoding repetitive DNA elements, such as Alu and long interspersed nucleotide elements, as a potential surrogate for gene-specific methylation studies. 33 Using micellular electrokinetic chromatography to assess genomic methylation, Lyko et al. 34 demonstrated decreased methylation in 3 of 4 MDS patients treated with DAC. Methylation was studied following the first cycle of DAC in only 2 patients. Significantly decreased methylation could be detected after cycle 2 in one patient, cycle 4 in a second patient, and cycle 5 in the third. However, when evaluable, karyotype normalization preceded changes in genomic methylation; thus, the methylation changes measured likely occurred in normal cells and were likely irrelevant to proximal molecular changes induced by DAC in the early treatment cycles. The small number of patients studied did not allow evaluation of the relationship between demethylation and clinical response.
The current data do not allow determination of the relevance of methylation changes to clinical response to DNMT inhibitors. Studies are hampered by the lack of a comprehensive panel of genes that are methylated in MDS and whose methylation status is known to impact the phenotype and biologic behavior of the disease. Studies have not examined methylation changes in different cellular compartments. Most studies have not examined changes early after drug treatment. Treatment with DNMT inhibitors may lead to activation of molecular pathways enabling terminal differentiation, apoptosis, or senescence. Through combining genomic methylation assays with genomic gene expression profiling in treated patients, researchers may identify important recurrent patterns that explain clinical response. Alternatively, the clinical activity of this class of drugs may be secondary to activation of pathways in response to DNA damage.
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Clinical Development of Histone Deacetylase Inhibitors in MDS
Increasing understanding of the important roles that post-translational modifications of histones play in establishing chromatin confirmation and gene transcription has led to interest in pharmacologic targeting of these changes to effect normal transcription patterns in malignant cells. Particular interest in the application of such approaches to MDS comes from the activity of DNMT inhibitors in MDS, suggesting important epigenetic mechanisms affecting MDS clinical behavior. Compounds with HDAC inhibitory activity typically induce p21 WAF1/CIP1 expression concomitant with cell cycle arrest and induction of terminal differentiation. 35 This effect led to the early application of these drugs in myeloid malignancies as potential differentiation inducers.
The earliest reported use of a compound with HDAC inhibitory activity in a myeloid malignancy was a case report of a pediatric patient with relapsed AML induced into remission using sodium butyrate. 36 Results showing in vitro activity of the butyrate analogue sodium phenylbutyrate (NaPB) in the growth arrest and differentiation of primary AML samples 37, 38 led to phase I studies of continuous infusion of NaPB in patients with MDS and AML. At a maximum tolerated dose of 375 mg/kg/d administered as an intravenous continuous infusion for 7 days, sustained plasma concentrations of 0.3 mM were achieved, within the range of concentrations with HDAC inhibitory activity. 39, 40 This dose was tolerated by most patients when administered for 7 of 28 days, 7 of 14 days, and 21 of 28 days. 39, 41 Dose-limiting toxicity was a reversible encephalopathy apparently caused by accumulation of the metabolite phenylacetate. 39 Hematologic improvement was seen in a small number of patients.
Valproic acid (VPA) has HDAC inhibitory activity similar to other small chain fatty acids. 42, 43 The clinical availability of oral formulations of VPA has led to various trials evaluating VPA as a putative HDAC inhibitor. A small study of patients with MDS or MDSrelated AML showed promising activity, with responses in 8 of 18 patients. This activity included a PR; however, response duration was brief (median 4 months). 44 As with the DNMT inhibitors, the relationship between clinical activity of these small chain fatty acids and their ability to inhibit HDAC and impact gene transcription has not yet been demonstrated.
Several more potent and potentially more specific HDAC inhibitors are under clinical investigation. These include the hydroxamic acid suberoylanilide hydroxamic acid (SAHA), the cyclic peptide FK228 (depsipeptide), and the benzamide MS-275. 45 The results of recent and current studies of these compounds in myeloid malignancies are not yet published.
Combination Therapies Targeting Epigenetic Mechanisms
Although monotherapy trials may help clarify the mechanism of drugs that putatively target epigenetic control of transcription, greatest clinical benefit may ultimately derive from biologically rational drug combinations. Binding of ligands to nuclear hormone receptors, such as the retinoic acid receptor, leads to the release of transcriptional corepressors, including HDACs. 46 Butyrate, phenylbutyrate, and VPA interact synergistically with ATRA on myeloid leukemia cells. 40, 42, 47, 48 NaPB and ATRA successfully induced remission in ATRA-resistant acute promyelocytic leukemia. 49 Preliminary reports of VPA plus ATRA suggest that this combination may have activity in MDS. Three of 11 elderly patients with AML developed complete marrow responses to this combination. 50 In another study, 6 of 20 elderly patients with AML or MDS developed hematologic improvement. 51 Several current trials focus on the combination of DNMT and HDAC inhibitors. Specific methylbinding proteins bind to methylated CpG dinucleotides and recruit transcriptional corepressors, including HDAC. 52 The sequential addition of HDAC inhibitors after DNMT inhibitors leads to additive or synergistic re-expression of methylated genes; HDAC inhibitors alone do not induce significant re-expression of heavily methylated genes. 53 Trials combining 5AC with NaPB and DAC with VPA in MDS and AML have been completed but are not yet published. 54 Current and upcoming trials combine 5AC with MS-275, DAC with SAHA, and 5AC with SAHA. Confirmation of any clinical benefit suggested by these combination trials will require randomized studies comparing the combination to the DNMT inhibitor alone.
Conclusions
As with all cancers studied to date, epigenetic changes contribute to abnormal gene transcription in MDS. Because of long-standing interest in effecting more normal differentiation in MDS bone marrow through the use of small molecules, prototypes for classes of drugs that target epigenetic changes were tested in MDS before the term epigenetic was coined. DNMT inhibitors represent the most active class of single agents for unselected MDS patients; hematologic responses occur in 50% to 60% of patients in low-and high-risk subsets. The mechanisms underlying the clinical activity of DNMT inhibitors in this group of diseases are unclear, and dissection of these mechanisms is critical to develop of better congeners and effective combination therapies. Similarly, first generation HDAC inhibitors were studied in MDS as putative differentiating agents and have mild-to-moderate hematologic activity. Based on promising preclinical models, combinations of DNMT and HDAC inhibitors form the basis of important ongoing clinical trials. Randomized trials that show that DNMT inhibitors prolong time to progression to AML or death suggest a very important class activity in the natural history of MDS. Unraveling the mechanism underlying this delay in disease progression might provide important insight into the biology of disease progression.
